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Abstract
Background: Obesity is associated with macrophage infiltration of adipose tissue, which may link adipose inflammation to
insulin resistance. However, the impact of inflammatory cells in the pathophysiology of obesity remains unclear. Tartrate
resistant acid phosphatase (TRAP) is an enzyme expressed by subsets of macrophages and osteoclasts that exists either as
an enzymatically inactive monomer or as an active, proteolytically processed dimer.
Principal Findings: Using mice over expressing TRAP, we show that over-expression of monomeric, but not the dimeric
form in adipose tissue leads to early onset spontaneous hyperplastic obesity i.e. many small fat cells. In vitro, recombinant
monomeric, but not proteolytically processed TRAP induced proliferation and differentiation of mouse and human
adipocyte precursor cells. In humans, monomeric TRAP was highly expressed in the adipose tissue of obese individuals. In
both the mouse model and in the obese humans the source of TRAP in adipose tissue was macrophages. In addition, the
obese TRAP over expressing mice exhibited signs of a low-grade inflammatory reaction in adipose tissue without evidence
of abnormal adipocyte lipolysis, lipogenesis or insulin sensitivity.
Conclusion: Monomeric TRAP, most likely secreted from adipose tissue macrophages, induces hyperplastic obesity with
normal adipocyte lipid metabolism and insulin sensitivity.
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Introduction
Adipocytes develop through a chain of events starting with the
proliferation of mesenchymal stem cells (MSC) which subsequently
differentiate into pre-adipocytes and finally into mature adipocytes
[1]. The exact mechanisms regulating these transitions are not
completely understood. Among transcription factors, peroxisome
proliferator-activated receptor gamma (PPARc) promotes adipo-
cyte differentiation [2], while GATA-2, GATA-3 and Wnt inhibit
[3,4] this process. Human adipose tissue-derived MSCs can
develop into multiple lineages including adipocytes, osteoblasts,
chondrocytes and myocytes [5]. Conversely, osteoblasts and
adipocytes are able to trans-differentiate [6–8], underscoring the
close relationship between these cell types. One possible regulator
of osteoblast differentiation and bone formation is the osteoclast-/
macrophage-derived metalloenzyme tartrate-resistant acid phos-
phatase (TRAP) [9,10].
TRAP, also known as purple acid phosphatase, uteroferrin or
type 5 acid phosphatase (Acp5), exists either as a latent monomeric
pro-enzyme of approximately 35 kDa or as a proteolytically
processed two-subunit enzyme of approximately 22 and 16 kDa
linked by a disulphide bridge [11,12]. The proteolytic processing
(exerted by, for instance, cathepsin K) excises part of an exposed
loop region close to the active site and is permissive for the
catalytic activation of TRAP [13]. TRAP has been shown to exist
intracellularly in various cell types and to be secreted in vivo by
osteoclasts [14,15] and in vitro by macrophages and osteoclasts
[16]. Intracellularly, TRAP is thought to participate in degrada-
tion of collagen fragments in osteoclasts [17,18] and of
phagocytosed bacteria in macrophages [19]. Osteoclast secreted
extracellular TRAP, on the other hand, has been proposed to
participate in the regulation of osteoclast adhesion and migration
[20]. However, the role of extracellular TRAP secreted from other
cell types, including macrophages, is unknown.
Macrophages are known to infiltrate adipose tissue during
development of obesity [21,22] and have been attributed a
function in the link behind obesity and insulin resistance [22,23].
In adipose tissue, macrophages have been proposed to secrete
factors that increases expression of inflammatory genes in
adipocytes [23,24] and inhibit adipogenesis [24,25]. Furthermore,
disruption of PPARc expression in macrophages predisposes mice
to development of obesity and insulin resistance [26].
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A clue to the link between macrophage infiltration of adipose
tissue and disordered adipocyte function came from the unex-
pected biology of a TRAP over-expressing mouse transgenic line.
To determine whether TRAP activity is limiting for bone
turnover, a transgenic line was produced in which multiple
additional copies of the complete gene were inserted in the germ
line. The mice showed increased bone turnover, and over-
expressed TRAP in the same locations as the endogenous genes
[10]. The line was originally generated on a complex mixed
genetic background. In the course of subsequent breeding and
backcrossing to the FVB/N background, a sub-line of the
transgenic mice was unexpectedly found to develop obesity. We
therefore investigated the phenotype of the obese and a lean sub-
line and also if TRAP can influence the proliferation and/or
differentiation of adipocyte precursor cells. In this study, we
present evidence that the obese phenotype in these animals is
causally linked to over-production of TRAP. We demonstrate that
certain macrophages in adipose tissue secrete monomeric TRAP
that induces insulin-sensitive obesity by formation of new small
adipocytes i.e. hyperplastic obesity. The results provide further
evidence of the complex multifunctional roles of TRAP.
Results
Transgenic over expression of monomeric, but not
proteolytically processed TRAP is associated with early
onset spontaneous hyperplastic obesity in mice
During breeding of a number of TRAP over expressing mouse
sub-lines derived from one of the original high-expressing founders
[10], we noted that one of these sub-lines (TRAP+) gained excessive
body weight after weaning and conspicuously developed spontane-
ous obesity (Figure 1A). The breeding of these lines was originally
undertaken in an attempt to identify a more penetrant bone
phenotype through association with other variables that affects bone
density. Comparison of organ weights in TRAP+ versus non-
transgenic littermate WT mice showed that two groups of organs
were increased in TRAP+ mice; (1) lymphoid organs i.e. spleen by
,50% and (2) different adipose tissue depots i.e. mesenteric- and
brown fat by,60–120% depending on depot (Figure 1B and Table
S2). On the other hand, the weights of other major internal organs
e.g. liver, heart and kidneys, relative to total body mass were reduced
in TRAP+ compared to WT mice. This increase in adipose tissue
depots in TRAP+ mice was neither associated with increased food
intake in adult males or females (Figure 1 C, D) nor increased
adipocyte cell volume (Figure 1E). However, mRNA levels for
several genes known to be associated with increased adipogenesis e.g.
PPARc (Z = 2.03 p = 0.042), glycerol-3-phosphate dehydrogenase
(GPDH; Z = 2.13 p = 0.033) and lipoprotein lipase (LPL; Z = 2.68
p = 0.01) were significantly up-regulated in adipose tissue from
TRAP+ compared to WT mice (Figure 1F).
The obese TRAP over expressing mouse sub-line (TRAP+) was
next compared to an apparently lean transgenic sub-line from the
same founder (TRAP+p). Comparison of growth curves of male
and female WT, TRAP+p and TRAP+ mice showed that TRAP+
mice weighed 20–40% more than either the non-transgenic WT
mice, or the lean transgenic TRAP+p mice (Figure 2 A, B and
Table S3) throughout the first year of life. In male and female
TRAP+ mice relative fat content was increased ,50% compared
to WT mice while lean body mass was decreased by ,12–14%
(Figure 2 C, D and Table S4). Neither relative lean nor fat mass
differed in male or female TRAP+p mice compared to WT mice.
Therefore, the obesity of the TRAP+ mice can be directly
attributed to the TRAP transgene, which appears necessary but
not sufficient to generate the phenotype.
The obese and lean TRAP over-expressing lines both expressed
elevated levels of TRAP mRNA (WT vs TRAP+ Z = 2.94
p = 0.003) in adipose tissue (Figure 2 E), so the basis of differential
adiposity is not due to differential expression of the transgene. The
difference between the sub-lines emerged when the proteins were
examined (Figure 2 F). The lean TRAP+p mice mainly expressed
proteolytically processed TRAP with increased enzyme activity
(WT vs TRAP+p Z = 3.80 p = 0.000143) (Figure 2E), whereas the
obese TRAP+ mice expressed both monomeric and proteolytically
processed TRAP in the adipose tissue (Figure 2F). We concluded
therefore that the lean mice more effectively cleave TRAP, so that
the obese mice, in effect, selectively over-express the monomeric
form of the protein with low enzyme activity.
Increased expression of monomeric, but not
proteolytically processed TRAP in adipose tissue from
obese humans
Based upon the observations in mice, we asked whether
monomeric TRAP is expressed in human adipose tissue, and
whether it is over-expressed in obese patients. Both TRAP mRNA
expression and monomeric TRAP protein expression were
increased by 400% among the obese subjects compared to lean
subjects (Figure 3A and Table S5). We also stratified the obese
patient group into one group displaying a mainly hypertrophic
phenotype (large fat cells) and one group displaying a more
pronounced hyperplastic phenotype (small fat cells) in spite of
similar body mass index. Although TRAP mRNA and monomeric
TRAP protein were elevated in both obese groups, (Figure 3 B–D
and Table S5), expression of proteolytically processed TRAP
appeared not to be different (Figure 3C).
Monomeric, but not proteolytically processed TRAP
induces adipogenesis ex vivo in adipocyte precursor cells
To determine whether expression of monomeric TRAP in
adipose tissue might have a direct causal role in generating obesity,
we used in vitro assays. Adipocyte progenitor cells were
simultaneously cultured under three different conditions; (1)
control (standard medium), (2) in the presence of monomeric
TRAP or (3) in the presence of proteolytically processed (cleaved)
TRAP. For assessing effects on proliferation, the TRAP isoforms
were present for 3 days in sub confluent, proliferating cultures. In
differentiating cultures, the TRAP isoforms were added to sub
confluent cultures for 2–3 days until confluence, as well as during
induction of adipocyte differentiation for an additional 4 days.
Monomeric TRAP, at 10211–10212 M, caused a 30% enhance-
ment of cell proliferation (Figure 4A and Table S6) and a 250%
increase of terminal adipocyte differentiation (Figure 4B) in the
mouse pre-adipocyte 3T3-L1 cell line. In contrast, proteolytically
processed TRAP affected neither proliferation nor differentiation of
this cell line (Figure 4A–B) in comparison to control cells. Similar
differential effects of monomeric vs. proteolytically processed TRAP
were also observed in adipocytes derived from human MSCs
(Figure 4C–D) as well as human pre-adipocytes (Figure 4E–F),
although at somewhat higher concentrations of monomeric TRAP.
The stimulation of differentiation by monomeric TRAP was
independent of the presence (Figure 4A, C, and E) or absence (data
not shown) of the PPARc activator roziglitazone.
Macrophages are a source of monomeric TRAP in
adipose tissue
In line with previous studies in animal models of obesity [21,22],
mRNA for c-fms (Figure 5A; Z = 2.72 p = 0.01) as well as F4/80
staining (Figure 5B) were increased in adipose tissue from obese
TRAP Induces Obesity
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TRAP+ mice indicative of an increase of infiltrating macrophages
in adipose tissue. The mouse TRAP gene contains multiple
promoters; the most proximal to the first coding exon contains a
compound start site region used selectively by macrophages and
osteoclasts [27]. A completely separate promoter upstream, which
generates an alternative 59UTR, is used by the hepatocytes and
renal tubule cells, which are the other major sites of TRAP
expression. The increased TRAP mRNA expression in TRAP+
adipose tissue (Figure 2E) probably originated from macrophages,
since the myeloid lineage–specific TRAP 1C transcript [27]
Figure 1. A transgenic TRAP over expressing mouse subline displays hyperplastic obesity. (A) Photograph of lean WT and obese TRAP+
mice. (B) Relative organ mass in TRAP+ compared to WT mice. (C) Food intake in male WT and TRAP+ mice. (D) Food intake in female WT and TRAP+
mice. (E) Adipocyte volume in WT and TRAP+ mice. (F) mRNA expression of adipocyte genes in adipose tissue from WT and TRAP+ mice.
doi:10.1371/journal.pone.0001713.g001
TRAP Induces Obesity
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constituted 87% of TRAP mRNA transcripts in both TRAP+ and
WT mice (Figure 5C). This is consistent with the analysis in the
original description of this transgene [10] in which over-expression
in macrophages and osteoclasts was directly demonstrated in tissue
and isolated cells. Consistent with the high conservation of the
TRAP promoter across species [27], in human adipose tissue,
TRAP was mainly expressed by cells in the stroma cell fraction
(TRAP mRNA in tissues vs cells; t =22.88 p = 0.008 df = 26)
(Figure 5D–E) identified by immunohistochemistry as CD68
positive macrophages (Figure 5F). Finally, we examined in vitro
Figure 2. Over expression of monomeric TRAP is associated with obesity in transgenic mice. (A) Growth curve of male obese TRAP+
(open square), lean TRAP+p (open circle) and WT (black square) mice. (B) Growth curve of female obese TRAP+ (open square), lean TRAP+p (open
circle) and WT (black square) mice. (C) Relative lean and fat mass in male WT, TRAP+p and TRAP+ mice. (D) Relative lean and fat mass in female WT,
TRAP+p and TRAP+ mice. (E) Expression of TRAP mRNA and enzyme activity in adipose tissue from WT, TRAP+p and TRAP+ mice. (F) Western blot of
TRAP in adipose tissue from WT, TRAP+p and TRAP+ mice.
doi:10.1371/journal.pone.0001713.g002
TRAP Induces Obesity
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whether macrophages can secrete monomeric TRAP. The
supernatant of the mouse macrophage cell line RAW 264.7
stimulated with LPS and IFN-c was shown to contain exclusively
monomeric TRAP (Figure 5G).
TRAP overexpression affects adipokine- and cytokine
profile in mouse adipose tissue and serum
Obesity in humans is associated with a so-called metabolic
syndrome which involves alterations in circulating levels of a wide
range of adipocyte and immune cell-derived cytokines, and
eventually with insulin resistance. We measured mRNA and
serum protein levels of cytokines and adipokines known to be
altered in obesity in TRAP+ and WT mice. These factors can be
divided into two groups: those only expressed by adipocytes
(adiponectin, leptin) [28] and those thought to be expressed by
several different cells in adipose tissue (TNFa, IL1b, MMP9, IL6,
CCL2) [28] The mRNA levels of leptin and adiponectin in
adipose tissue were found to be unchanged between the TRAP+
mice and WT littermates (Figure 6A). The serum leptin levels were
two-fold increased (Figure 6A; Z =22.83 p = 0.004) in the
TRAP+ compared to WT mice, probably reflecting the overall
increase in total body fat (and total fat cell number). The mRNA
level of TNFa in adipose tissue was increased (Figure 6B; Z = 2.34
p = 0.019) in TRAP+ mice compared to WT littermates although
serum TNFa levels were not (data not shown). The mRNA levels
for CCL2, MMP9, IL1b, IFNc, IL12b, TGFb and IL6 were not
significantly affected in the adipose tissue of TRAP+ mice
(Figure 6B), suggesting that there is not a global activation of
macrophages to produce inflammatory cytokines.
Transgenic mice over expressing TRAP have normal
adipocyte lipid metabolism and insulin sensitivity
Adipocytes isolated from TRAP+ mice exhibited normal
spontaneous basal lipolysis (Figure 6C, D), normal responses to
addition of noradrenaline (Figure 6C) and insulin (Figure 6D) on
lipolysis and unchanged basal or maximum insulin induced
lipogenesis (Figure 6E). Half-maximum effective concentrations
of insulin and noradrenaline to elicit metabolic responses were also
similar in adipocytes from WT and TRAP+ mice (data not shown).
Thus, adipocyte metabolism and insulin sensitivity were normal in
TRAP+ mice. In line with the finding in adipocytes, serum levels
of glucose and insulin as well as HOMA index did not differ
between the TRAP+ mice and their non-transgenic WT controls
(Figure 6F).
Figure 3. Expression of TRAP mRNA and protein in human adipose tissue. (A) Expression of TRAP mRNA and monomeric TRAP protein in
obesity compared to the lean state. (B) TRAP mRNA, (C) total TRAP protein and (D) monomeric TRAP protein expression in hyperplastic and
hypertrophic obesity.
doi:10.1371/journal.pone.0001713.g003
TRAP Induces Obesity
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Discussion
TRAP overexpressing mice were originally generated in order
to study the skeletal phenotype and bone turnover [10].
Unexpectedly, in the course of breeding to a different genetic
background we found one sub-strain of TRAP over expressing
mice that presented an early onset obesity that did not seem to be
due to apparent over-eating. The differences in body weight
(,20–40%) was evident already at one month of age and up to
1 year of age the body weight curves in TRAP+ and WT mice
were parallel. This indicates that other features such as decreased
physical activity/energy expenditure could explain the obesity in
TRAP+ animals. It is of interest to note that there was clear
relative difference in organ size of TRAP+ animals, where most
internal organs were relatively smaller in the TRAP+ mice
compared to WT mice. This might suggest that adipose tissue
expanded in TRAP+ mice leading to redistribution of energy
expenditure on behalf of other organs which diminished in size.
In the TRAP over expressing mice, adipocyte volume was
normal and several genes known to increase adipogenesis (PPARc,
GPDH and LPL) were up regulated. This suggested that the
obesity was largely due to enhanced formation of new fat cells
through differentiation and/or proliferation rather than lipid
filling of pre-existing adipocytes, i.e. the TRAP+ mouse develops
hyperplastic obesity. Only two previous models have demonstrated
hyperplasia, rather than hypertrophy, as the major cause of obesity
[29,30]. The results also suggested that the monomeric form of
TRAP is specifically causing the effect of TRAP on adipogenesis.
A second sub-strain (TRAP+p) without detectable expression of
monomeric TRAP, but with elevated levels of the proteolytically
processed form in adipose tissue was lean.
Since the lines derive from the same founder, and over-express
the mRNA and total protein to the same extent, we suggest that
there is an independently segregating variant allele of a gene
involved in the proteolytic processing of TRAP. Assuming this
Figure 4. Stimulation of adipocyte proliferation and differentiation by monomeric TRAP but not proteolytically processed TRAP.
The following cells were used: Mouse 3T3-L1 preadipocytes (A, B), Human mesenchymal stem cells (hMSC) (C, D) and human pre-adipocytes (E, F).
Proliferation (BrdU) was assessed after 1 day (3T3-L1), 2 days (3T3-L1, hMSC), 3 days (3T3-L1) or 5 days (pre-adipocytes) after seeding. Differentiation
(GPDH-activity) was measured 4 days (3T3-L1) or 12 days (hMSC, pre-adipocytes) after start of differentiation. hMSC were treated with TRAP either
before (Pro) or at (Post) confluence. mTRAP=monomeric TRAP, cTRAP=proteolytically processed TRAP. Data are expressed as percentage of control.
Statistical analysis was performed using T-test, * p,0.05, comparing control cells with stimulated cells.
doi:10.1371/journal.pone.0001713.g004
TRAP Induces Obesity
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Figure 5. Macrophages are the primary source of monomeric TRAP in mouse and human adipose tissue. (A) mRNA expression of the
monocyte/macrophage marker F4/80 and c-fms in adipose tissue of TRAP+ vs. WT mice. (B) Immunohistochemistry of mouse macrophage marker F4/
80 in adipose tissue from TRAP+ compared to WT mice (C) mRNA for the myeloid lineage specific TRAP transcript 1C in adipose tissue of WT and
TRAP+ mice. (D) Expression of monomeric TRAP in adipose tissue (T) and isolated adipocytes (Ad) from five subjects (Pat 1–5). (E) TRAP mRNA
expression in human adipose tissue and in isolated adipocytes. (F) Co-localization between monomeric or total TRAP and the macrophage marker
CD68 in subcutaneous human adipose tissue from a representative subject. (G) Monomeric TRAP is secreted from the mouse macrophage cell line
RAW 264.7 (lane 1), whereas proteolytically processed TRAP is not detectable (lane 2).
doi:10.1371/journal.pone.0001713.g005
TRAP Induces Obesity
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allele exists, it was acquired fortuitously in a complex breeding
history from the original transgene, so the process clearly cannot
be repeated precisely. This may pose a limitation to generate
sublines of the desired phenotype, but since the original transgene
construct gave very reproducible over-expression, new founders
could be readily back-crossed to different inbred mouse strains to
generate congenic strains in order to recapitulate the ‘‘obese’’
phenotype on more defined genetic backgrounds. We can assume
that the corresponding ‘‘lean’’ allele could be identified genetically
by performing a genome scan of a set of individual lean and fat
individuals and a candidate genetic interval could be refined by
intercrossing lean and fat sublines. It may also be that screening
inbred mouse lines for a preponderance of monomeric TRAP
could identify the genetic origin of the allele. Finally, comparative
array profiling of macrophages from the two sub lines could also
contribute to identification of a presumptive candidate modifier
Figure 6. Metabolic and inflammatory profile of adipose tissue from obese TRAP over expressing mice. (A) Levels of leptin and
adiponectin mRNA and serum protein in WT and TRAP+ mice. (B) Inflammatory gene expression profile in the TRAP+ mice. (C) Noradrenalin-
stimulated lipolysis in isolated adipocytes from TRAP+ and WT mice. (D) Insulin-inhibitable lipolysis in isolated adipocytes from TRAP+ and WT mice.
(E) Insulin- stimulated lipogenesis in isolated adipocytes from TRAP+ and WT mice. (F) Levels of blood glucose and insulin in TRAP+ mice.
doi:10.1371/journal.pone.0001713.g006
TRAP Induces Obesity
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gene that is specific to ‘‘lean’’ animals. Alternatively, generating
transgenic mice using for instance the aP2 promoter to direct over
expression of the TRAP gene selectively to adipocyte lineage cells
may provide another viable strategy to obtain mice with the obese
phenotype.
TRAP knock out mice [31] have not been reported to have an
altered adipose tissue phenotype, although our work would suggest
more detailed studies would be worthwhile. This does not
necessarily imply that monomeric TRAP has no role in normal
adipose development, since the role of TRAP in bone is also partly
redundant (the knockout animals are only mildly osteopetrotic).
An interesting feature of the TRAP-over expressing transgenic
mice is that there is an increased macrophage content in adipose
tissue, so TRAP is directly or indirectly proinflammatory. A
systemic effect of TRAP on macrophages could also underlie the
increase in relative spleen size in these animals. It may be that in
adipose tissue, as in bone, there is a complex homeostatic
interaction between TRAP-producing and TRAP-responsive cells.
It is interesting to note that elevated levels of serum TRAP
previously has been positively correlated with serum insulin levels
in NIDDM rat models [32]. In osteoclasts the post-translational
proteolytic processing of TRAP is partly involving the cysteine
protease cathepsin K [33]. Cathepsin K has been shown to be a
marker of adiposity [34] and cathepsin K null mice gained less
weight when put on high-fat diet and exhibited increased
adipocyte lipolysis [35]. However, while TRAP seems to be
mainly expressed in macrophages, cathepsin K seems to be
expressed in the adipocyte itself [36] suggesting distinct roles for
these proteins in adipose tissue.
The clear relevance of the mouse model was demonstrated in
human patient material, where an increased expression of
monomeric TRAP, but not proteolytically processed TRAP, was
apparent in adipose tissue of obese subjects. Human obesity is
commonly characterized by a combination of hypertrophic and
hyperplastic adipose tissue, although hypertrophy usually domi-
nates [37,38], but some subjects exhibit predominantly hyperplas-
tic (i.e. smaller adipocyte volume than expected) obesity [39].
When our obese subjects were divided according to fat cell size
both TRAP mRNA and monomeric TRAP were showed a
tendency to a further increase in those with hyperplastic obesity as
compared to those with hypertrophic obesity.
In both hMSC and pre-adipocytes from mouse and humans
monomeric TRAP stimulated both proliferation and differentia-
tion, measured as increase of GPDH enzyme activity. However,
proteolytically processed TRAP had no effect on these processes.
These data are somewhat unexpected, as usually a positive effect
on proliferation is accompanied by a negative effect on
differentiation and the opposite. Nevertheless, the findings are
consistent with the hypothesis that monomeric TRAP could exert
a dual effect on both proliferation and differentiation of pre-
adipocytes which would increase the impact of monomeric TRAP
although the effect was small in each step. It is, however, possible
that the adipogenic effect of monomeric TRAP is stronger in vivo
than in vitro. The effect on differentiation in vitro was observed in
the presence or absence of roziglitazone suggesting that mono-
meric TRAP can activate adipogenesis at variable levels of PPARc
activity. Although TRAP has not been shown previously to affect
the proliferation and differentiation of adipocytes, TRAP has been
shown to induce differentiation of osteoblasts [9] and haemato-
poietic cells [40].
Obesity is associated with a low-grade inflammation in adipose
tissue [41,42], where a hall-mark is influx of macrophages into the
tissue [21,22]. The latter has been hypothesized to be a
consequence of adipocyte necrosis because of adipocyte hypertro-
phy [43] and/or increase of monocyte attractants such as MCP-1/
CCL2 [44–46]. TRAP is normally expressed in cells from the
myeloid linage [11,47,48] and since the construct in the transgenic
TRAP over expressing mouse used in this study is under the
influence of the normal TRAP promoter [10] we expected that
only cells normally competent to express TRAP would have an
elevated expression of the enzyme. Confirming this idea, we found
that in mouse adipose tissue, almost 90% of the TRAP transcripts
originated from the myeloid specific transcript 1C and in human
adipose tissue, TRAP were mainly expressed in CD68 positive
macrophages. This indicates that the main source of TRAP in
adipose tissue is macrophages. It should be noted, however, that
CD68 is expressed in cell types other than macrophages, e.g.
fibroblasts, although the antibody used in this study has been
shown to recognize CD68 preferably in macrophages [49].
It is unlikely that monomeric TRAP is secreted by other cells
than macrophages since the 1C transcript, which is the
predominant transcript in adipose tissue, is regulated by PU.1
and MiTF which are myeloid specific transcription factors [50].
Furthermore, the TRAP staining in the original transgene study
[10] does not support the idea that significant levels of TRAP can
be expressed by non myeloid cells other than in liver and kidney.
However, we cannot rule out that secretion of TRAP from cells
other than macrophages occur within adipose tissue.
In macrophages, TRAP has traditionally been considered a
lysosomal constituent. However, recent studies in osteoclasts has
shown that there is likely to be two populations of TRAP present,
one intracellular which is mainly proteolytically processed and one
secreted which is mainly monomeric [33]. Previously published
data [16] as well as in vitro experiments of this study have shown
that monomeric TRAP can be secreted also from macrophages in
vitro. This is also in line with other studies showing that
monomeric, rather than proteolytically processed TRAP seems
to be the dominant secreted form also in other cell types [13,51].
Together these data suggest that also in macrophages different
isoforms of TRAP might be present intracellularly or secreted.
Once secreted from macrophages, monomeric TRAP seemingly
acts on adipose tissue to induce adipogenesis. The molecular
mechanism behind the action of monomeric TRAP on adipogen-
esis is unknown, but it can be speculated that TRAP is recognized
by a surface receptor on pre-adipocytes and that signals from this
receptor regulate adipogenesis.
Obesity is strongly linked to insulin resistance [52,53] and
several studies have highlighted the correlation between adipocyte
size rather than adipose tissue mass and insulin malfunction [53–
58]. The enlargement of adipocytes may not have pathophysio-
logical significance by itself but rather be a manifestation of other
pathogenetic factors leading to insulin resistance [58–60], such as
increased adipocyte lipolysis resulting in elevated fatty acids, which
in turn cause insulin resistance [61]. On the other hand, enlarged
adipocytes may be pathogenic themselves by, for example, a
change in production of adipokines and cytokines [58], the latter
linking adipose inflammation to insulin resistance. Recently it was
also shown that TNFa down regulates eNOS expression in
metabolically active tissues which might sustain obesity [62].
Certain macrophage populations in adipose tissue might be
associated with insulin resistance and obesity [26]. As judged by
circulating insulin and glucose levels as well as HOMA index and
by measurement of adipocyte lipolysis and lipogenesis, the obese
TRAP+ mouse exhibited normal adipocyte lipid and glucose
metabolism as well as insulin and catecholamine sensitivity,
although it can not be excluded that some alterations of insulin
action occurred in skeletal muscle or liver, which were not directly
examined. Also, there was no evidence of major changes in
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expression of adipokines or cytokines involved in obesity mediated
insulin resistance except for an increased mRNA expression of
TNFa. Thus, the absence of fat cell hypertrophy and the modest
change in expression of cytokines associated with an innate
immune response may explain why obese TRAP+ mice had nor or
little evidence of insulin resistance or altered fat cell metabolism in
spite of macrophage infiltration. The enhanced number of
adipocytes in the enlarged adipose tissue might cause the increased
level of circulating leptin in TRAP+ mice.
In light of these data, we propose a hypothesis of a paracrine
effect of monomeric TRAP on adipogenesis. In this model,
monomeric TRAP, likely secreted predominantly by macrophag-
es, influences the development of obesity by inducing adipogenesis
in a situation where there is an influx of macrophages into the
adipose tissue or an up regulation of monomeric TRAP in pre-
existing macrophages. This could increase the formation of new,
normally sized adipocytes with normal insulin sensitivity and
metabolism. This hypothesis is not apparently consistent with the
proposed function of macrophages in adipose tissue, since they
previously have been reported to secrete factors that increases
expression of inflammatory genes in adipocytes [23,24] and
inhibits adipogenesis [24,25]. However, macrophages consist of a
heterogeneous population of cells and can be activated differently
[63] and evidence was recently presented for the presence of
distinct macrophage populations in adipose tissue some being
protective against insulin resistance [64]. With respect to
expression of monomeric and proteolytically processed TRAP in
macrophages it has been shown that monomeric TRAP has a
more restricted distribution than proteolytically processed TRAP
[11]. However, the regulation of the different forms of TRAP in
macrophages remains to be elucidated. Thus, macrophages,
depending on their progeny and/or activation state, might secrete
factors, for example monomeric TRAP, which could have variable
effects on adipose tissue.
In summary, certain macrophages in adipose tissue seem to
secrete monomeric TRAP that induces obesity; at least partly due
to adipogenic affects causing increased formation of normally sized
adipocytes with normal insulin sensitivity, lipid and carbohydrate
metabolism and adipokine/chemokine production.
Materials and Methods
Experimental animals
Age-matched male and female mice from different litters (WT ,
TRAP+p and TRAP+) were kept under controlled light/dark
conditions with food and water available ad libitum. The study
was approved by the Stockholm South Animal Ethical Committee
(S159/01 and S235/04) and maintained according to the
guidelines of the Animal Welfare Board at Karolinska Institutet.
Statistical analysis
For statistical method and number of animals or subjects for
each experiment see specific analysis. Values are given as
mean6SD. Symbols for statistical comparison are * p,0.05;
**p,0.01; ***p,0.005. NS; not significant
Generation and genotyping of TRAP over expressing
transgenic FVB/N mice
TRAP over expressing transgenic FVB/N mice [10] (TRAP+ or
TRAP+p) containing .30 copies of the TRAP gene were used.
Genomic DNA was purified using Puregene (Gentra, Minneapolis,
MN) from mouse-tails. Primers (Invitrogen, Carlsbad, CA)/probes
(Biosearch Technologies, Novato, CA) for SV40 and TRAP were as
follows; (A) SV40 primers 59CACCTGGTTGCTG ACTAAT
TGAGA 39/59GTGTGTCAGTTAGGGTGTGGAAA 39 and
HEX labeled probe 59CCCCAGGCTCCCCAGCAGGCAG 39
annealing temperature 62uC. (B) TRAP primers 59 TGGTCATTT-
CTTTGGGG CTTATCT 39/59GCTACTTGCGGTTTCAC-
TATGGA 39 and FAM labeled probe 59TGTGA AGCCGCC-
CAGGGAGTCCTC 39 annealing temperature 62uC. qPCR was
run as stated under ‘‘Total RNA purification and RT-qPCR’’ with
the exception that iQ Supermix (Bio-Rad, Hercules, CA) was used.
Determination of organ weight index
Organs were dissected out and the wet weights were
determined. For n see Table S2. Statistical analysis was carried
out using Mann-Whitney U test.
Determination of body weight–growth curves
Male (WT; n = 50, TRAP+p; n = 21, TRAP+; n = 56; for n at
specific ages see Table S3) and female (WT; n = 68, TRAP+p;
n = 22, TRAP+; n = 52; for n at specific ages see Table S3) were
weighed at different time points. Statistical analyses were carried
out using Kruskal Wallis followed by Mann Whitney U test.
Measurement of lean mass and body fat content using
DXA
Dual-energy X-ray absorptiometry (DXA) was performed as
described [65]. Male (WT; n = 24, TRAP+p; n = 17, TRAP+;
n = 5) and female (WT; n = 28, TRAP+p; n = 14 , TRAP+; n = 9 ),
2–12 month mice were used (Supplementary Table IV). Statistical
analysis was carried out using Kruskal Wallis test followed by
Mann-Whitney U test.
Calculation of adipocyte volume
Adipocyte size was determined as described in [66]. Adipose
tissue was obtained from the animals (WT; n = 8, TRAP+; n = 8)
and adipocytes were isolated by collagenase treatment. Using
direct microscopy, the diameter of 100 cells was determined and
the mean fat cell volume was calculated. Statistical analysis was
carried out using ANOVA.
Measurement of food intake
Animals were given a specific amount of food and the
consumption was measured by weighing the remaining food every
other day for two weeks. Food consumption was then calculated as
intake of gram food/gram body weight over two weeks for male
(WT; n = 3, TRAP+; n = 6) and female (WT; n = 3, TRAP+; n = 5)
mice. Statistical analysis was carried out using Mann-Whitney U test.
Total RNA purification and RT-qPCR on mouse and
human adipose tissue
Total RNA was extracted from gonadal or mesenteric adipose
tissue of male and female mice (WT; n = 11, TRAP+p; n = 7,
TRAP+; n = 9) using RNeasy Lipid Tissue Mini Kit (QIAGEN,
Hilden, Germany), treated with DNase (Invitrogen, Carlsbad,
CA), quantified using Ribogreen (Invitrogen, Carlsbad, CA) and
then transcribed using iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA). From human subjects, total RNA was extracted
from 300 mg subcutaneous fat tissue (n = 28) using RNeasy Mini
Kit (QIAGEN, Hilden, Germany), determination of RNA purity
and reverse transcription was performed as described [67]. Real-
Time PCR was carried out on an iCycler iQ Real Time PCR
Detection System (Bio-Rad, Hercules, CA) in triplets using, for
mouse cDNA, PlatinumH SYBRH Green qPCR SuperMix UDG
(Invitrogen, Carlsbad, CA) and, for human cDNA, iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA) both with the addition
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of 10 nM fluorescein (Bio-Rad, Hercules, CA) in a final volume of
25 ml. Program setting for mouse samples were as follows: 2 min at
50uC, 2 min at 95uC, 40 cycles of 15 sec at 95uC and 30 sec at
62–64uC (depending on primer pair). Program setting for human
samples were as follows: 10 min at 95uC, 40 cycles of 15 sec at
95uC 20 sec at 63uC. For primer information see Table S1. Primer
pairs were optimized prior to use for primer concentration and
annealing temperature to achieve PCR amplification efficiency
between 95–105%. Mouse samples were normalized towards b-
actin and human samples towards GAPDH. Relative quantifica-
tion of mRNA was calculated using the ‘‘Comparative Ct method’’
as described in User Bulletin 2 from Applied Biosystems. For mice,
statistical analysis was carried out using Mann-Whitney U test and
for humans using ANOVA (Table S5).
Measurement of TRAP enzyme activity
TRAP enzyme activity was measured [68] in tissue homoge-
nates prepared as follows. Adipose tissue from male and female
mice (WT; n = 11, TRAP+; n = 10, TRAP+p; n = 10) was
homogenized in 0.15 M KCl+0.1% Triton X-100+Pefabloc
(10 mg/ml)+Complete, Protease Inhibitor Cocktail Tablets (1
tablet/50 ml solution) (Boehringer Mannheim, Mannheim, Ger-
many) and centrifuged at 3200 6 g for 30 minutes. The
supernatant was then assayed for TRAP enzyme activity.
Human studies
Human abdominal subcutaneous adipose tissue was obtained
from different sources. For the isolation of pre-adipocytes and
mesenchymal stem cells (MSC), tissue was obtained as the product of
cosmetic liposuction on otherwise healthy non-obese women (body
mass index ( = BMI): 22–36 kg/m2; age 22–56 years; n = 10). For
immunohistochemistry, tissue was obtained during surgery from
three obese subjects undergoing gastric banding. For the comparison
of gene and protein expression in lean versus obese subjects a frozen
(270uC) 300 mg tissue piece was used. It was obtained by needle
biopsy from lean (BMI,25 kg/m2) or obese (BMI.30 kg/m2) but
otherwise healthy women participating in ongoing studies of the
genetic regulation of human fat cell function. For those in the gene
expression study age (mean6SD) was 36614 and 3967 years in
lean (n = 14) and obese (n = 14) subjects, respectively. BMI was
2362 and 3664 kg/m2 respectively. Fat cell volume was 4506140
and 8226240 pL in lean and obese, respectively. The obese group in
the gene expression study was sub-divided in two groups according
to fat cell size; hyperplasia (fat cell volume of 6416450 pL; n = 7) and
hypertrophia (cell volume of 10046490 pL; n = 7) with no between
group difference in BMI. In the protein expression study age was
4064 years (lean (n = 7)) and 40613 years (obese (n = 12)), the BMI
was 2361 kg/m2 and 3865 kg/m2, and fat cell volume was
4906190 pL and 8686223 pL, respectively. The obese group was
sub-divided into a hyperplastic (fat cell volume 6596420 pL; n = 6)
and hypertrophic (fat cell volume 10776570 pL; n = 6) group) with
no between group difference in BMI. The human ethics committee
at the Karolinska University Hospital Huddinge approved the study,
which was explained in detail to each subject and written informed
consent was obtained. Unpaired t-test was used to compare lean and
obese subjects and adipose tissue versus adipocytes. ANOVA was
used to compare lean subjects with the hypertrophic and
hyperplastic groups. Degrees of freedom in these experiments were
1, 1 and 2, respectively.
Electrophoresis and immunoblot analysis
Partially purified [11] culture media from 16106 RAW 264.7 cells
or 70mU TRAP from WT/TRAP+p/TRAP+ adipose tissue was
subjected to SDS-PAGE using 12% NuPage gels (Invitrogen,
Carlsbad, CA) run with MOPS buffer and transferred to PVDF
membranes (Bio-Rad, Hercules, CA). Membranes were blocked
using 1% TBST (100 mM Tris-HCl pH 7.6, 154 mM NaCl, 1%
Tween-20) and stained with rabbit anti-mouse monomeric TRAP
[11] 1:1500 or rabbit anti-rat total TRAP 1:1500 [69], goat anti-
rabbit HRP 1:10 000 (Calbiochem, La Jolla, CA) and developed
using Renaissance (NEN Life Science, Boston, MA). Human
samples; 100 mg of total protein total obtained from protein lysates
was separated on 12% PAA-gels, transferred onto PVDF mem-
branes and stained using rabbit anti-mouse monomeric TRAP or
rabbit anti-rat total TRAP as described above. Bands were detected
using SupersignalH (Pierce, Rockford, IL). Relative expression was
determined using Chemidoc XRS System (Bio-Rad, Hercules, CA).
Immunohistochemistry
Immunohistochemistry was carried out mainly as previously
described [11]. Mouse adipose tissue from male and female mice;
paraffin sections (WT; n = 3, TRAP+; n = 3) were treated with
0.1% trypsin (Sigma-Aldrich, St. Louis, MO) at 37uC for
30 minutes and stained for macrophages using F4/80 monoclonal
antibody (1:50) (Serotec, Oxford, UK). ChemMate Detection Kit
Peroxidase/DAB rabbit/mouse (Dako, Glostrup, Denmark) was
used as secondary antibodies and developing solution. Human
adipose tissues; microwave treated (1mM EDTA pH 8 for
10 minutes at 900 W) paraffin sections were stained with rabbit
anti-rat total TRAP 1:50 [69] recognizing both monomeric and
the two-subunit TRAP or rabbit anti-mouse monomeric TRAP
antibody 1:50 [11] and CD68 1:100 (Dako, Glostrup, Denmark).
Secondary antibodies were ALEXA 568 goat anti-rabbit Fab2
1:250 and ALEXA 488 goat anti-mouse Fab2 fragments 1:100
(Invitrogen, Carlsbad, CA). Sections were then examined using a
Leica TCS NT ArKr laser confocal microscope (Leica Micro-
systems AG, Wetzler, Germany).
Expression, purification and cleavage of recombinant rat
TRAP
Recombinant rat TRAP was expressed in Sf9 insect cells and
purified as described [70]. To generate the proteolytically
processed form, recombinant rat TRAP was digested at 37uC
for 40 minutes with recombinant human cathepsin K (kindly
provided by Dr. Robert Dodds) in 5mM NaAc pH 5.5, 1 mM
EDTA and 10 mM DTT using a 1:1 molar ratio.
Proliferation and differentiation of 3T3-L1 cells in the
presence of TRAP
For proliferation experiments (n = 4, df = 3); 3T3-L1 (ATCC
(LGC Promochem, Bora˚s, Sweden)) cells (2,000 cells/cm2) were
cultured in DMEM/F12 Glutamax II, 4.5 g/L glucose, 1.5 g/L
sodium bicarbonate, penicillin/streptomycin, 2.5% calf bovine
serum +/2 cleaved (600 U/mg) or monomeric (50 U/mg) TRAP
(1029 M–10212 M). After 24, 48 and 72 h, cells were labeled for 2 h
with BrdU, fixed and BrdU incorporation was measured using Cell
Proliferation ELISA, BrdU kit (Roche, Mannheim, Germany).
For differentiation experiments (n = 4, df = 3); 3T3-L1 cells
(6,000 cells/cm2) were grown into confluence in DMEM/F12
Glutamax II, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate,
penicillin/streptomycin, 10% calf bovine serum +/2 cleaved or
monomeric TRAP (1029 M–10212 M)). At 2–3 days after conflu-
ence, 0.5 mM isobutylmethylxanthine, 1 mM dexamethasone and
10 mg/ml bovine insulin was added to the media to start
differentiation. Cells were then cultured +/2 roziglitazone
(1 mM), cleaved (600 U/mg) or monomeric (50 U/mg) TRAP
(1029 M–10212 M). After 48 h, dexamethasone, isobutylmethyl-
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xanthine and roziglitazone were omitted. After an additional 48h
(i.e. 4 days after the start of differentiation), cells were lysed and
GPDH activity was measured [71]. Statistical analysis was
performed using t-test.
Proliferation and differentiation of human mesenchymal
stem cells derived from adipose tissue in presence of
TRAP
Human MSC were isolated from a subcutaneous lipoaspirate,
grown to 60–70% confluence and passage for at least 20 passages,
as described [72]. For proliferation experiments (n = 3, df = 2);
hMSC (passage 9) (2,000 cells/cm2) were cultured in DMEM
Glutamax I, 1 g/L glucose, penicillin/streptomycin, 2.5% fetal
bovine serum in the presence or absence of cleaved (600U/mg) or
monomeric (50U/mg) TRAP (1029 M–10212 M). After 48 h,
cells were labeled for 2h with BrdU, fixed and BrdU incorporation
was measured as described above.
For differentiation experiments (n = 3, df = 2); hMSC (passage
18) were differentiated as described [72] in the presence or
absence of cleaved or monomeric TRAP (1029 M). Twelve days
after the start of differentiation cells were lysed and GPDH activity
was measured [71]. Statistical analysis was performed using t-test.
Differentiation and proliferation of preadipocytes
isolated from human adipose tissue in presence of TRAP.
Isolation of pre-adipocytes were performed as previously
described [73]. For proliferation experiments (n = 3, df = 2); cells
(4000 cells/cm2) were cultured in growth medium containing
2.5% fetal bovine serum in the presence or absence of cleaved or
monomeric TRAP (1029 M–10212 M). After 5 days, cells were
labelled for 2 h with BrdU, fixed and BrdU incorporation was
measured as described above. For differentiation experiments
(n = 3, df = 2); cells were differentiated as described [74] in the
presence or absence of cleaved (600U/mg) or monomeric (50 U/
mg) TRAP (1029 M–10212 M). Twelve days after the start of
differentiation, cells were lysed in GPDH buffer and GPDH
activity was measured as described [71]. Statistical analysis was
performed using t-test.
Secretion of TRAP from macrophages
RAW 264.7 cells were cultured in a 37uC humidified 5% CO2
atmosphere in DMEM media (Gibco, St Louis, MO) supplement-
ed with 10% FCS (Gibco, St Louis, MO) and 0.1 mg/ml
gentamycin (Gibco, St Louis, MO). For stimulation, 0.256106
RAW 264.7 cells/ml (passage 3) was treated with IFNc (500 U/
ml) (Invitrogen, Carlsbad, CA) for 16 h., and then with LPS
(1 ng/ml) (Sigma-Aldrich, St. Louis, MO) for an additional 24 h.
Metabolic studies on the TRAP over expressing mice
Lipolysis and lipogenesis experiments were conducted on
isolated adipocytes as described [73] on fat (pooled fractions of
gonadal, mesenteric and inguinal fat from the same animal) from
male and female mice (WT; n = 8 and TRAP+; n = 8). After a 2 h
incubation, the cell suspension was subjected to measurement of
active uptake into total fat cell lipids (lipogenesis index). Statistical
analysis was performed using ANOVA.
Measurement of glucose, insulin and HOMA index
Glucose (WT; n = 3 and TRAP+; n = 3), HOMA index (WT;
n = 3 and TRAP+; n = 3) and insulin (WT; n = 8 and TRAP+;
n = 3) were determined individually on serum from male and
female mice, using a Monarch automated analyzer (ILS
Laboratories Scandinavia AB, Sollentuna, Sweden) or a RIA
assay (Linco Research Inc., St. Charles, MO), respectively.
Statistical analysis was performed using Mann-Whitney U test.
Measurement of serum leptin, adiponectin and TNFa
Serum levels of leptin in male and female mice .4 months of
age (WT; n = 26 and TRAP+; n = 13) (Quantikine Mouse Leptin
Immunoassay, R&D Systems, Inc., Minneapolis, MN), of
adiponectin in male and female mice .4 months of age (WT;
n = 11 and TRAP+; n = 7) (Adiponectin Mouse ELISA, BioVen-
dor, Heidelberg, Germany) and of TNFa in male and female mice
.4 months of age (WT; n = 8 and TRAP+; n = 5) (Ready-Set-Go!
Mouse TNFa ELISA, ebioscience, San Diego, CA) was measured.
Statistical analysis was carried out using Mann-Whitney U test.
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